azacitidine has been researched along with Blood Diseases in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q; Li, M; Qiu, H; Sun, A; Wu, D; Wu, X; Zhang, J; Zhou, L | 1 |
| Chandran, NS; Koh, XQ; Ooi, XT; Sun, Y; Tan, CL | 1 |
| Caglioti, F; Gianfelici, V; Giugliano, E; Levato, L; Mannella, A; Molica, S; Russo, A | 1 |
| Becerra, C; Conkling, P; Dong, Q; Kellerman, A; Kingsley, EC; Kolibaba, K; Laille, E; Morris, JC; Rifkin, RM; Savona, MR; Skikne, BS; Ukrainskyj, SM | 1 |
| Kunacheewa, C; Owattanapanich, W; Thongthang, P; Ungprasert, P; Utchariyaprasit, E | 1 |
| Abboud, CN; Cashen, AF; Choi, J; DiPersio, JF; Fiala, MA; Gao, F; Holt, M; Jacoby, MA; Pusic, I; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Westervelt, P | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Braester, A; Ellis, M; Filanovsky, K; Goldschmidt, N; Herishanu, Y; Kirgner, I; Mittelman, M; Ofran, Y; Oster, HS; Perri, C; Raanani, P; Rosenbaum, H | 1 |
| Aul, C; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Lübbert, M; Platzbecker, U | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Berger, EG; Fehr, J; Thurnher, M | 1 |
| Berger, EG; Rusconi, S; Thurnher, M | 1 |
| Berger, EG | 1 |
| Aparicio, A; Weber, JS | 1 |
| Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA | 1 |
| Abele, R; Bruntsch, U; Clavel, M; Dodion, P; Gundersen, S; Pinedo, HM; Renard, J; Smyth, J; van Glabbeke, M | 1 |
4 review(s) available for azacitidine and Blood Diseases
| Article | Year |
|---|---|
A systematic review and meta
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cohort Studies; Female; Hematologic Diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2019 |
Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Topics: Azacitidine; Germany; Hematologic Diseases; Humans; Myelodysplastic Syndromes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Tn-syndrome.
Topics: Anemia, Hemolytic; Antibodies, Monoclonal; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Azacitidine; Blood Cells; Erythrocyte Membrane; Galactosyltransferases; Hematologic Diseases; Humans; Lectins; Leukopenia; Molecular Structure; Syndrome; Thrombocytopenia | 1999 |
Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Agents; Hematologic Diseases; Humans; Neoplasms | 2002 |
5 trial(s) available for azacitidine and Blood Diseases
| Article | Year |
|---|---|
Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fatigue; Female; Food; Food-Drug Interactions; Gastric Acidity Determination; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Proton Pump Inhibitors | 2018 |
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Topics: Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Azacitidine; Combined Modality Therapy; Decitabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Young Adult | 2015 |
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites; Azacitidine; Bone Marrow; Disease-Free Survival; DNA Methylation; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Quality of Life; Risk; Thalidomide; Treatment Outcome | 2016 |
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged | 1985 |
The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Decitabine; Female; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Neoplasms | 1987 |
7 other study(ies) available for azacitidine and Blood Diseases
| Article | Year |
|---|---|
Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nausea; Oncogene Proteins, Fusion; Sulfonamides; Transplantation, Haploidentical; Treatment Outcome; Vomiting | 2020 |
A retrospective analysis of dermatological problems in haematology and oncology patients at a tertiary Singapore hospital.
Topics: Antibodies, Bispecific; Antineoplastic Agents; Azacitidine; Bortezomib; ErbB Receptors; Hematologic Diseases; Humans; Immunotherapy; Neoplasms; Pemetrexed; Pyrimidines; Retrospective Studies; Singapore; Skin Diseases; Tertiary Care Centers | 2020 |
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine.
Topics: Antineoplastic Agents; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Oncogene Proteins, Fusion; Remission Induction; Sulfonamides | 2020 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Differences in the regulation of specific glycosylation in the pathogenesis of paroxysmal nocturnal hemoglobinuria and the Tn-syndrome.
Topics: Adult; Alleles; Antigens, CD; Azacitidine; Bone Marrow; Butyrates; Butyric Acid; CD48 Antigen; CD8 Antigens; Cells, Cultured; Flow Cytometry; Galactosyltransferases; Gene Expression Regulation, Enzymologic; Glycosylation; Hematologic Diseases; Hemoglobinuria, Paroxysmal; Humans; Leukosialin; Male; Sialoglycoproteins; T-Lymphocytes | 1994 |
Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome.
Topics: Alleles; Antigens, Tumor-Associated, Carbohydrate; Azacitidine; Butyrates; Butyric Acid; Carbohydrate Sequence; Clone Cells; Enzyme Repression; Galactosyltransferases; Hematologic Diseases; Humans; Kinetics; Molecular Sequence Data; Syndrome; T-Lymphocytes; Tumor Cells, Cultured | 1993 |